Interview with Byoung Joo Gwag, CEO, President, Neurotech Pharmaceuticals
What was the vision behind the creation of Neurotech back in 1998, originally as a Research Center, and then as an independent bio-tech company? It all began in 1998 when…
Address: 4F Hyunwoo Building, Gomae- dong 381-1, Giheung-gu, Yongin -si, Gyeonggi-do446-901, Republic of Korea
Tel: 82-31-215-9985
Web: http://gntpharma.com/intro/
Established in 1998 Neurotech Pharmaceuticalshas received the G7 Project Award from the Ministry of Science & Technology:Development of Alzheimer’s Disease models and Neuroprotectant compounds.Neurotech team members are working diligently with shareholder support to develop the next generation of medicines.Neurotech has been developing Neu2000 and AAD-2004 over the last 8 years and has recently discovered two additional promising compounds. Neurotech has also expanded its drug development capabilities over this period. In preparing for competition in the global marketplace, Neurotech has secured sufficient cash flow for R&D Funding through public listing, employing a conservative business model, and establishing a new drug development infrastructure through the introduction of IT. Its partner, Eolith, is a company that specializes in Broadband Convergence Network technology. Neurotech is working with Eolith and large medical center to construct a Ubiquitous Health Monitoring System (UHMS) to select patients with stroke and Alzheimer’s and maximize the efficacy of drugs. Neurotech ultimately seeks to gain entry into the pharmaceutical industry through clinical studies and the marketing of new drugs.In 2008, Neurotech has successfully completed the Neu2000 clinical phase I study in the U.S.
What was the vision behind the creation of Neurotech back in 1998, originally as a Research Center, and then as an independent bio-tech company? It all began in 1998 when…
National OncoVenture (NOV) is Korea’s Ministry of Health and Welfare funded oncology drug development program to nurture oncology innovation in the country. To maintain high access and limit costs of…
Seung-Kyou Lee, vice-president of Korea Bio gives his assessment on the current landscape for biotech firms in Korea. He also discusses Korea Bio’s programme to create a further 1000 biotech…
Young-Whan Park, president of National OncoVenture, discusses their programme to support oncology drug development in South Korea, with a view to discovering and producing a globally competitive, Korean-made oncology medicine.…
Christoph Heider, president of the European Chamber of Commerce in Korea (ECCK), discusses the organization, the need for the modernization of the Europe-South Korea Free Trade Agreement, and the future…
Southeast Asia’s notoriously strict anti-cannabis laws could be set to relax dramatically as South Korea becomes the first country in the region to legalise cannabis for medicinal use. This…
Sunyoung Kim, CEO and founder of ViroMed, reveals his strategy for conquering the US market and the feasibility of his ambitions for ViroMed to become the biotech company with the…
In an exclusive interview, Tae-Han Kim, president and CEO of Samsung Biologics, documents his strategy for expanding Samsung’s operations into biologics, and how Samsung Biologics has rapidly become one of…
Professor Dukgeun Ahn of Seoul National University, trade policy advisor to the Ministry of Health offers his insights into the current policies towards the healthcare industry in Korea, and the…
South Korea’s proposed Moon Jae-In Care has been subject to both praise and protest this year. President Moon Jae-in’s plan dubbed “Moon Care” will be implemented in stages throughout 2022…
Jongmoon Kim, CEO of ToolGen discusses the potential for their CRISPR technology to revolutionize not only therapy for genetic illnesses, but also agriculture. Kim explains his move from information technology…
JungTae Park, senior managing director of KoBIA (Korea Biomedicine Industry Association), describes the achievements of the association as a bridge between industry and government. He also highlights the potential of…
Jia Liu, CEO of DreamCIS, a Korean CRO, part of the Chinese company Tigermed, talks about her vision for DreamCIS to be “the CRO everybody wants to work with”. Liu…
See our Cookie Privacy Policy Here
